"Magic medicine" becomes an ideal partner for cancer immunotherapy?

Immune checkpoint inhibitors ( ICIs ) targeting the programmed cell death -1 ( PD-1 ) / programmed cell death - ligand 1 ( PD-L1 ) pathwayare a standard treatment option for cancer patient.

Immune checkpoint inhibitors ( ICIs ) targeting the programmed cell death -1 ( PD-1 ) / programmed cell death - ligand 1 ( PD-L1 ) pathway are a standard treatment option for cancer patient.

Statins are widely prescribed cholesterol-lowering drugs that inhibit 3- hydroxy- 3 -methylglutaryl-CoA by inhibiting the rate-limiting enzyme of the mevalonate pathway, which supports tumorigenesis and is unregulated in cancer ( HMG-CoA ) conversion to mevalona.

Patient characteristics in the original cohort

Patient characteristics in the original cohort

Table 1 shows the clinical characteristics of the 390 patients enrolled in this stud.

Table 1 shows the clinical characteristics of the 390 patients enrolled in this stud.

Table 2 summarizes patients' baseline characteristics according to statin treatment, statin use or nonuse associated with age, sex, smoking history, BMI , and mutation status in the original cohort ( P <0001 , P=0036 , P=0085 , P= 0032 and P= 0508.

Table 2 summarizes patients' baseline characteristics according to statin treatment, and statin use or nonuse was associated with age, sex, smoking history, BMI , and mutation status in the original cohort ( P < 0001 , P =0036 , P P= 0085 , P P= 0032 and P P= 0508 .

Survival analysis results of the original cohort

Survival analysis results of the original cohort

The effect of statin treatment on survival in the original cohort was first investigat.

The effect of statin treatment on survival in the original cohort was first investigat.

We next investigated the effect of statin treatment on survival in a propensity score-matched coho.

In this multicenter and retrospective study, no significant differences in PFS and OS were observed between NSCLC patients treated with and without statins in the original cohor.

In this multicenter and retrospective study, no significant differences in PFS and OS were observed between NSCLC patients treated with and without statins in the original cohor.

 

Original source:

Original source:

Takada, Kazuki et .

Takada, Kazuki et .
“A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective stu.
”BMC cancer v.
22,1 50 6 M.

2022, doi:11186/s12885-022-09385- BMC cancer leave a message here